Clinical trials: Type Two Diabetes Mellitus
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets…
- Trial name
- NCT07694115
- Testing
- Empagliflozin / Metformin Extended-Release Tablet, Synjardy XR tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes, Diabetes Mellitus, Type 2
Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers
This trial is conducted in Japan. The aim of this trial is to compare biphasic insulin aspart 70 (NN2000-Mix70) in subjects with type 2 diabetes with that of biphasic insulin aspart 30 (NN-X14Mix30) in healthy volunteers.
- Trial name
- NCT01538511
- Testing
- biphasic insulin aspart 70, biphasic insulin aspart 30
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus
This is a double-blind, randomised, controlled, two period crossover phase Ib trial using an individualized standard meal with a fixed nutrient ratio in subjects with type 1 diabetes mellitus to investigate postprandial blood…
- Trial name
- NCT02528396
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06792968
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Diabetes Mellitus, Type 2
Insulin Glulisine in Type 2 Diabetic Patients
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled…
- Trial name
- Basal Plus (NCT00360698)
- Testing
- Insulin Glargine, Glimepiride, Insulin Glulisine
- Where
- 3 sites in United States, Russia and 1 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Type 2 Diabetes
A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)
This study will assess the pharmacokinetics of two formulations of MK-1006. The primary hypothesis of this study is that the MK-1006 area under the curve (0 to infinity) and maximum concentration after administration of a single…
- Trial name
- NCT00979459
- Testing
- MK-1006 DFC, MK-1006 FCT
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
An open label, balanced, randomized, single dose, two treatment, two sequence, two period, two way crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
- Trial name
- NCT06932159
- Testing
- Empagliflozin + Linagliptin film-coated tablets, Glyxambi film-coated tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with…
- Trial name
- DUAL™ II (NCT01392573)
- Testing
- insulin degludec/liraglutide, insulin degludec
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 413 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
- Trial name
- NCT02737891
- Testing
- Tesofensine/Metoprolol
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Saniona
Clamp Study
A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients
Pharmacokinetics and pharmacodynamics study of 2 formulation of insulin glargine (RinGlar® GEROPHARM vers. Lantus® Sanofi-Aventis)
- Trial name
- NCT04101383
- Testing
- RinGlar®, Lantus®
- Where
- 2 sites in Russia
- Volunteers
- 42 people
- Sponsor
- Geropharm
Diabetes, Diabetes Mellitus, Type 2
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) once daily in insulin naïve subjects with type 2 diabetes…
- Trial name
- BEGIN™ (NCT01326026)
- Testing
- insulin degludec
- Where
- 45 sites in United States, Finland and 2 more
- Volunteers
- 222 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients.
- Trial name
- SPOTLIGHT (NCT07456774)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2
The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase and improves second phase insulin response in subjects with diabetes mellitus type 2.
- Trial name
- RESTORE (NCT00931372)
- Testing
- Lixisenatide (AVE0010)
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
The purpose of this study is to evaluate the effect of steady-state ranolazine 500 mg bid on the steady state pharmacokinetics (PK) of metformin in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01546558
- Testing
- Metformin, Ranolazine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 1
Mylan Insulin Glargine Study
The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D products produced from two manufacturing processes (Process V and Process VI) in combination with insulin lispro in patients with type 1…
- Trial name
- NCT03376789
- Testing
- MYL-1501D product using manufacture process V, MYL-1501D product using manufacture process VI
- Where
- 38 sites in United States
- Volunteers
- 219 people
- Sponsor
- Mylan Inc.
Diabetes Mellitus, Type 2
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.
- Trial name
- NCT00418522
- Testing
- Insulin glargine, Inhaled Insulin (Exubera)
- Where
- 73 sites in United States, Puerto Rico
- Volunteers
- 413 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three…
- Trial name
- NCT00960661
- Testing
- exenatide, insulin lispro, Metformin
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 1,036 people
- Sponsor
- AstraZeneca